These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23921963)

  • 41. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
    Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
    Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Significance of microcystic, elongated, and fragmented glandular-like features in intraductal papillary mucinous neoplasm of the pancreas.
    Park JY; Lee JH; Song KB; Hwang DW; Kim KR; Kim SC; Hong SM
    Hum Pathol; 2018 Aug; 78():18-27. PubMed ID: 29410139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression.
    Mohri D; Asaoka Y; Ijichi H; Miyabayashi K; Kudo Y; Seto M; Ohta M; Tada M; Tanaka Y; Ikenoue T; Tateishi K; Isayama H; Kanai F; Fukushima N; Tada M; Kawabe T; Omata M; Koike K
    J Gastroenterol; 2012 Feb; 47(2):203-13. PubMed ID: 22041919
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
    Molin MD; Matthaei H; Wu J; Blackford A; Debeljak M; Rezaee N; Wolfgang CL; Butturini G; Salvia R; Bassi C; Goggins MG; Kinzler KW; Vogelstein B; Eshleman JR; Hruban RH; Maitra A
    Ann Surg Oncol; 2013 Nov; 20(12):3802-8. PubMed ID: 23846778
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cripto-1 overexpression is involved in the tumorigenesis of gastric-type and pancreatobiliary-type intraductal papillary mucinous neoplasms of the pancreas.
    Hong SP; Lee EK; Park JY; Jeon TJ; Bang S; Park S; Chung JB; Lee WJ; Kim H; Song SY
    Oncol Rep; 2009 Jan; 21(1):19-24. PubMed ID: 19082438
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plectin-1 as a Biomarker of Malignant Progression in Intraductal Papillary Mucinous Neoplasms: A Multicenter Study.
    Moris M; Dawson DW; Jiang J; Lewis J; Nassar A; Takeuchi KK; Lay AR; Zhai Q; Donahue TR; Kelly KA; Crawford HC; Wallace M
    Pancreas; 2016 Oct; 45(9):1353-8. PubMed ID: 27101571
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular profile of apomucin and p53 protein as predictors of malignancy in intraductal papillary mucinous neoplasms of the pancreas.
    Mizumoto M; Honjo G; Kobashi Y; Awane M; Matsusue S
    Hepatogastroenterology; 2011; 58(110-111):1791-5. PubMed ID: 22086702
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases.
    Chakraborty S; Swanson BJ; Bonthu N; Batra SK
    J Clin Pathol; 2010 Jul; 63(7):579-84. PubMed ID: 20591909
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Reprimo Down-regulation on Malignant Transformation of Intraductal Papillary Mucinous Neoplasm.
    Nakazato T; Suzuki Y; Tanaka R; Abe N; Masaki T; Mori T; Ohkura Y; Sugiyama M
    Pancreas; 2018 Mar; 47(3):291-295. PubMed ID: 29401170
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas.
    Matthaei H; Norris AL; Tsiatis AC; Olino K; Hong SM; dal Molin M; Goggins MG; Canto M; Horton KM; Jackson KD; Capelli P; Zamboni G; Bortesi L; Furukawa T; Egawa S; Ishida M; Ottomo S; Unno M; Motoi F; Wolfgang CL; Edil BH; Cameron JL; Eshleman JR; Schulick RD; Maitra A; Hruban RH
    Ann Surg; 2012 Feb; 255(2):326-33. PubMed ID: 22167000
    [TBL] [Abstract][Full Text] [Related]  

  • 51. miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts.
    Matthaei H; Wylie D; Lloyd MB; Dal Molin M; Kemppainen J; Mayo SC; Wolfgang CL; Schulick RD; Langfield L; Andruss BF; Adai AT; Hruban RH; Szafranska-Schwarzbach AE; Maitra A
    Clin Cancer Res; 2012 Sep; 18(17):4713-24. PubMed ID: 22723372
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monoclonal antibodies recognizing the non-tandem repeat regions of the human mucin MUC4 in pancreatic cancer.
    Jain M; Venkatraman G; Moniaux N; Kaur S; Kumar S; Chakraborty S; Varshney GC; Batra SK
    PLoS One; 2011; 6(8):e23344. PubMed ID: 21886786
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
    Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinicopathological features of intraductal papillary neoplasms of the bile duct: a comparison with intraductal papillary mucinous neoplasm of the pancreas with reference to subtypes.
    Fukumura Y; Nakanuma Y; Kakuda Y; Takase M; Yao T
    Virchows Arch; 2017 Jul; 471(1):65-76. PubMed ID: 28550497
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas.
    Ishida M; Egawa S; Aoki T; Sakata N; Mikami Y; Motoi F; Abe T; Fukuyama S; Sunamura M; Unno M; Moriya T; Horii A; Furukawa T
    Pancreas; 2007 Nov; 35(4):348-52. PubMed ID: 18090241
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sonic hedgehog is an early developmental marker of intraductal papillary mucinous neoplasms: clinical implications of mRNA levels in pancreatic juice.
    Ohuchida K; Mizumoto K; Fujita H; Yamaguchi H; Konomi H; Nagai E; Yamaguchi K; Tsuneyoshi M; Tanaka M
    J Pathol; 2006 Sep; 210(1):42-8. PubMed ID: 16794990
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of RNAi-mediated MUC4 gene silencing on the proliferation and migration of human pancreatic carcinoma BxPC-3 cells.
    Li Y; Wu C; Chen T; Zhang J; Liu G; Pu Y; Zhu J; Shen C; Zhang Y; Zeng N; Zhang X
    Oncol Rep; 2016 Dec; 36(6):3449-3455. PubMed ID: 27748843
    [TBL] [Abstract][Full Text] [Related]  

  • 58. p53 protein expression in intraductal papillary mucinous tumors (IPMT) of the pancreas as an indicator of tumor malignancy.
    Kawahira H; Kobayashi S; Kaneko K; Asano T; Ochiai T
    Hepatogastroenterology; 2000; 47(34):973-7. PubMed ID: 11020860
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas.
    Yokoyama S; Higashi M; Kitamoto S; Oeldorf M; Knippschild U; Kornmann M; Maemura K; Kurahara H; Wiest E; Hamada T; Kitazono I; Goto Y; Tasaki T; Hiraki T; Hatanaka K; Mataki Y; Taguchi H; Hashimoto S; Batra SK; Tanimoto A; Yonezawa S; Hollingsworth MA
    Oncotarget; 2016 Jul; 7(27):42553-42565. PubMed ID: 27283771
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas.
    Akimoto Y; Nouso K; Kato H; Miyahara K; Dohi C; Morimoto Y; Kinugasa H; Tomoda T; Yamamoto N; Tsutsumi K; Kuwaki K; Onishi H; Ikeda F; Nakamura S; Shiraha H; Takaki A; Okada H; Amano M; Nishimura S; Yamamoto K
    Pancreatology; 2015; 15(4):432-8. PubMed ID: 26052067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.